Replies to post #557675 on NorthWest Biotherapeutics Inc (NWBO)

[beartrap12]

Vator, I hope somebody with more knowledge than me will answer your question, but I’ll give it a shot:

Explain to me why a royalty stream is necessary? Any oncologist could pair DCVax once approved with an approved adjuvant. A partnership not even with an adjuvant position could get part of the revenue stream with a partnership on trial funding.

I can see royalties from Flaskworks if the system is set up at the site of surgery.

I do not see the argument for multiple partnerships. Feel free to explain why.

I have actually had the same question.
1)Does NWBO holding a patent license for combos make it mandatory for other companies to pay us a royalty in order to use our product with theirs? I’m talking over and above the cost of our product?

2) do other companies have to go through clinical trials with DCVax in order to find out what the timing should be for using their product with ours, and how much product to use, etc.?

3) Or are we actually creating a new product for the Pharma when they combo with us so they can extend their exclusive use protection against generic copies for years to come?

4) Or is it all about the possibility that some products may be useless in some cancers, such as Keytruda on GBM, but have synergy with DCVax creating a situation where the two products together produce double and triple the long term survival over DCVax alone? Clinical trials are necessary to prove this.

5) Then there’s the issue that while DCVax is safe, other immunotherapies can actually speed up death in patients, so perhaps doctors are not going to try to combine products without the guidance of a clinical trial to set guidelines for them to follow and assure them that they are trying something on their patient that is as safe as it can be?

Please somebody jump in and help us out here.